Abstract:The role of radiotherapy (RT) and stereotactic radiosurgery (SRS) as adjuvant or salvage treatment in high-grade meningiomas (HGM) is still debated. Despite advances in modern neuro-oncology, HGM (WHO grade II and III) remains refractory to multimodal therapies. Published reports present aggregated data and are extremely varied in population size, exclusion criteria, selection bias, and inclusion of mixed histologic grades, making it extremely difficult to draw conclusions when taken individually. This current work aims to gather the existing evidence on RT and SRS as adjuvants following surgery or salvage treatment at recurrence after multimodality therapy failure and to conduct a systematic comparison between these two modalities. An extensive systematic literature review and meta-analysis were performed. A total of 42 papers were eligible for final analysis (RT n = 27; SRS n = 15) after searching MEDLINE via PubMed, Web-of-science, Cochrane Wiley, and Embase databases. Adjuvant regimens were addressed in 37 papers (RT n = 26; SRS n = 11); salvage regimens were described in 5 articles (RT n = 1; SRS n = 4). The primary outcomes of the study were the overall recurrence rate and mortality. Other actuarial rates (local and distant control, OS, PFS, and complications) were retrieved and analyzed as secondary outcomes. A total of 2853 patients harboring 3077 HGM were included. The majority were grade II (87%) with a mean pre-radiation volume of 8.7 cc. Adjuvant regimen : 2742 patients (76.4% RT; 23.6% SRS) with an overall grade II/III rate of 6.6/1. Lesions treated adjSRS were more frequently grade III (17 vs 12%, p < 0.001), and received subtotal resection (57 vs 27%, p = 0.001) compared to the RT cohort. AdjSRS cohort had a significantly shorter mean follow-up than adjRT (36.7 vs 50.3 months, p = 0.01). The overall recurrence rate was 38% in adjRT vs 25% in adjSRS ( p = 0.01), while mortality did not differ between the groups (20% vs 23%, respectively; p = 0.80). The median time to recurrence was 1.5 times longer in the RT group ( p = 0.30). Five-year local control was 55% in adjRT and 26% in adjSRS ( p = 0.01), while 5-year OS was 73% and 78% ( p = 0.62), and 5-year PFS was 62% and 40% in adjRT and adjSRS ( p = 0.008). No difference in the incidence of complications (24% vs 14%, p = 0.53). Salvage regimen: 110 patients (37.3% RT; 62.7% SRS) with a grade II/III rate of 8.6/1. The recurrence rate was 46% in salRT vs 24% in salSRS ( p = 0.39), time to recurrence was 1.8 times longer in the salRT group (35 vs 18.5 months, p = 0.74). Mortality was slightly yet not significantly higher in salRT (34% vs 12%, p = 0.54). Data on local and distant control were only available for salSRS. The 5-year OS was 49% and 83% ( p = 0.90), and the 5-year PFS was 39% and 50% in salRT and salSRS ( p = 0.66), respectively. High-grade meningiomas (WHO grade II and III) receiving adjuvant RT showed a higher overall recurrence rate than meningiomas receiving adjuvant SRS. The adjRT cohort, however, achieved higher 5-year LC and PFS rates, thus suggesting a potentially longer time to recurrence compared to adjSRS patients, who, meanwhile, experienced a significantly shorter follow-up. This result must also consider the higher number of grade III lesions and the smaller extent of resection achieved in the adjSRS group. Overall mortality did not differ between the two groups. No differences in outcome measures were observed in salvage regimens.

379 Meningioma Molecular Groups Predict Response to Adjuvant Radiotherapy Following Surgery

Abstract 2346: Meningioma molecular classification predict response to surgical resection and adjuvant radiotherapy: An integrated clinicomolecular analysis

Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma

Efficacy of Adjuvant Radiotherapy for Atypical and Anaplastic Meningioma

Prognostic Model That Predicts Benefits of Adjuvant Radiotherapy in Patients with High Grade Meningioma

The Evolving Classification of Meningiomas: Integration of Molecular Discoveries to Inform Patient Care

Progesterone Receptor Expression and Prediction of Benefits of Adjuvant Radiotherapy in De Novo Atypical Meningiomas after Gross-Total Resection.

Clinical implications of DNA methylation-based integrated classification of histologically defined grade 2 meningiomas

1245 Malignant Meningioma Survival, Recurrence and Functional Outcomes in an International Multicenter Cohort

Postoperative Adjuvant Radiotherapy in Atypical Meningioma Patients: A Meta-Analysis Study

Rbio-04. Outcomes Of Radiosurgery For Who Grade 2 Meningiomas: The Role Of Ki-67 Index In Guiding The Tumor Margin Dose

Prognostic role of extent of resection and adjuvant radiotherapy in de novo anaplastic meningiomas

Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients

Current experimental therapies for atypical and malignant meningiomas

206 Spinal Meningioma: An Institutional Case Series With Preliminary Results of Molecular Profiling

Molecular diagnosis and treatment of meningiomas: an expert consensus (2022)

Radt-20. Postoperative Radiotherapy Provides Additive Progression-Free Survival Benefit In Atypical Meningiomas Regardless Of Extent Of Resection

Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort

Efficacy of radiotherapy and stereotactic radiosurgery as adjuvant or salvage treatment in atypical and anaplastic (WHO grade II and III) meningiomas: a systematic review and meta-analysis

Tmet-21. Metabolic Profiling Of Meningioma Reveals Novel Subgroup-Specific Biologic Insights And Outcome Dependencies

Correlations Between Genomic Subgroup and Clinical Features in a Cohort of More Than 3000 Meningiomas.